Cost effectiveness of zanamivir for the treatment of influenza in a high risk population in Australia.
- 1 June 2000
- journal article
- clinical trial
- Published by Springer Nature in PharmacoEconomics
- Vol. 17 (6) , 611-620
- https://doi.org/10.2165/00019053-200017060-00007
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- A Pharmacoeconomic Model for the Treatment of InfluenzaPharmacoEconomics, 1999
- Randomised trial of efficacy and safety of inhaled zanamivir in treatment of influenza A and B virus infections. The MIST (Management of Influenza in the Southern Hemisphere Trialists) Study Group.1998
- Randomised trial of efficacy and safety of inhaled zanamivir in treatment of influenza A and B virus infectionsThe Lancet, 1998
- Influenza vaccination among the elderly in South AustraliaThe Medical Journal of Australia, 1997
- Estimating the Dollar Value of Health Outcomes from Drug-Abuse InterventionsMedical Care, 1996
- Economic Evaluation of Influenza Vaccination and Economic ModellingPharmacoEconomics, 1996
- A quality-of-life method for estimating the value of avoided morbidity.American Journal of Public Health, 1992
- Estimating the Value of Avoiding Morbidity and Mortality from Foodborne IllnessesRisk Analysis, 1991
- The Swine-Influenza DecisionNew England Journal of Medicine, 1976
- Analysis of a tuberculin testing program using a health status indexSocio-Economic Planning Sciences, 1972